Ann: Resmed to Announce Third Quarter 2015 Results, page-56

Keep calm all - fat price targets are being thrown around.. from CITI $11

RMD will come back can we go 100% again? Wowee if we can tweak a few things.. all highlighted and discussed

28/4/2015

0119 GMT [Dow Jones] New products launched by medical respiratory devices specialist ResMed (RMD.AU) are gaining traction but its margins are under pressure, Citi says. The firm's third-quarter revenue rose 13%, with new products such as its Astral, Air Sense 10 and Air Curve 10 devices doing better than expected. However, Citi notes gross margins were weak at 59.5%. Still, the brokerage reckons the stock is attractive, trading at about 21 times forward earnings. It has a buy recommendation but trims its target to A$11.01/share from A$11.87 after cutting earnings per share forecasts by about 5% and 9% for financial years 2016 and 2017, respectively. RMD is down 2.7% at A$8.23. ([email protected];



Companies Mentioned

ResMed Inc RMD:NYS

Health Care Equipment & Services Sector - Large Cap Stock